KIDNEY DISEASE AND HYPERTENSION IN BLACKS

在一项关于招募可行性的试点研究中，这项建议如下： 黑人高血压病患者的病情控制及随访 肾功能。 第一阶段为期12个月(92年7月至93年6月) 每月四人会议期间的礼宾和操作手册 临床中心、数据协调中心和NIDDK项目 协调员(S)。 第二阶段(93年7月至94年6月)，招募至少25名样本 有记录的舒张期高血压和肾功能减退的黑人患者。 这25名患者将被随机分配到四个治疗组中的一个：斯坦- 标准治疗与血管紧张素转换酶抑制剂治疗的比较 和/或钙通道阻滞剂，以及在每个治疗中的分配 组分为两个水平的舒张压控制：一般(MAP<107 mm Hg)和攻击性(HAP<92 mm Hg)。血压与肾功能 (125I-异硫代氨基甲酸盐GFR测量)将在 12个月的随访期。第三阶段(九四年七月至九五年三月)为期九个月 数据分析的结束期。 为了实现RFA的目标，我们提供了一个协作的PRO- 波萨尔来自埃默里大学和莫尔豪斯医学院。这将是 提供大量市中心黑人高血压患者的通道 肾功能减退的患者，一个经验丰富的团队 招募少数族裔参与者参加临床试验 临床研究中心，工作人员接受过输液技术和 血液和尿液样本的精确计时，以及调查人员 擅长研究影响肾脏进展的变量 高血压患者的疾病。 这一结果将提高对高血压过量的理解。 与Sion相关的黑人终末期肾脏疾病，并提供指南 进行全面的临床合作试验。

This proposal in a pilot study of the feasibility of recruitment, ran- domization and follow-up of hypertensive black patients with reduced renal function. Phase I is a 12-month period (Jul 92 - Jun 93) for development of a protocol and manual of operations during monthly meetings of four clinical centers, the data coordinating center and NIDDK project coordinator(s). Phase II (Jul 93 - Jun 94), is recruitment of a sample of at least 25 black patients with documented diastolic HBP and reduced renal function. These 25 patients will be randomized to one of four treatment arms: stan- dard therapy versus therapy with angiotensin converting enzyme inhibitors and/or calcium channel blockers, and assignment within each treatment group to two levels of diastolic BP control: usual (MAP less than 107 mm Hg) and aggressive (HAP less than 92 mm Hg). BP and renal function (125-I iothalamate GFR measurements) will be assessed serially during a 12-month follow-up period. Phase III (Jul 94 - Mar 95) is a 9-month close-out period for data analysis. To accomplish the objectives of the RFA, we offer a collaborative pro- posal from Emory University and Morehouse School of Medicine. This will provide access to a large number of inner-city black hypertensive patients with reduced renal function, a team highly experienced in recruitment of minority participants into clinical trials, a General Clinical Research Center with staff trained in infusion techniques and precise timing of blood and urine specimens, and investigators with expertise in research on variables that influence progression of renal disease in hypertensive patients. The results will improve the understanding of the excess of hyperten- sion-related end-stage renal disease in blacks, and provide guidelines for a full-scale cooperative clinical trial.